Kinase Activities in Pancreatic Ductal Adenocarcinoma with Prognostic and Therapeutic Avenues

Overview

Journal Mol Oncol

Specialties Molecular Biology
Oncology

Date 2024 Apr 23

PMID 38650175

Authors

Andrea Valles-Marti

Richard R de Goeij-de Haas

Alex A Henneman

Sander R Piersma

Thang V Pham

Jaco C Knol

Joanne Verheij

Frederike Dijk

Hans Halfwerk

Elisa Giovannetti

Connie R Jimenez

Maarten F Bijlsma

Affiliations

Soon will be listed here.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a limited number of known driver mutations but considerable cancer cell heterogeneity. Phosphoproteomics provides a direct read-out of aberrant signaling and the resultant clinically relevant phenotype. Mass spectrometry (MS)-based proteomics and phosphoproteomics were applied to 42 PDAC tumors. Data encompassed over 19 936 phosphoserine or phosphothreonine (pS/T; in 5412 phosphoproteins) and 1208 phosphotyrosine (pY; in 501 phosphoproteins) sites and a total of 3756 proteins. Proteome data identified three distinct subtypes with tumor intrinsic and stromal features. Subsequently, three phospho-subtypes were apparent: two tumor intrinsic (Phos1/2) and one stromal (Phos3), resembling known PDAC molecular subtypes. Kinase activity was analyzed by the Integrative iNferred Kinase Activity (INKA) scoring. Phospho-subtypes displayed differential phosphorylation signals and kinase activity, such as FGR and GSK3 activation in Phos1, SRC kinase family and EPHA2 in Phos2, and EGFR, INSR, MET, ABL1, HIPK1, JAK, and PRKCD in Phos3. Kinase activity analysis of an external PDAC cohort supported our findings and underscored the importance of PI3K/AKT and ERK pathways, among others. Interestingly, unfavorable patient prognosis correlated with higher RTK, PAK2, STK10, and CDK7 activity and high proliferation, whereas long survival was associated with MYLK and PTK6 activity, which was previously unknown. Subtype-associated activity profiles can guide therapeutic combination approaches in tumor and stroma-enriched tissues, and emphasize the critical role of parallel signaling pathways. In addition, kinase activity profiling identifies potential disease markers with prognostic significance.

References

Collisson E, Bailey P, Chang D, Biankin A . Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2019; 16(4):207-220. DOI: 10.1038/s41575-019-0109-y. View

Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov J . Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011; 27(12):1739-40. PMC: 3106198. DOI: 10.1093/bioinformatics/btr260. View

Song M, Song S, Kim S, Oh H, Lim D . The tumour suppressor RASSF1A promotes MDM2 self-ubiquitination by disrupting the MDM2-DAXX-HAUSP complex. EMBO J. 2008; 27(13):1863-74. PMC: 2486425. DOI: 10.1038/emboj.2008.115. View

Wilkes M, Murphy S, Garamszegi N, Leof E . Cell-type-specific activation of PAK2 by transforming growth factor beta independent of Smad2 and Smad3. Mol Cell Biol. 2003; 23(23):8878-89. PMC: 262664. DOI: 10.1128/MCB.23.23.8878-8889.2003. View

Supadmanaba I, Mantini G, Randazzo O, Capula M, Muller I, Cascioferro S . Interrelationship between miRNA and splicing factors in pancreatic ductal adenocarcinoma. Epigenetics. 2021; 17(4):381-404. PMC: 8993068. DOI: 10.1080/15592294.2021.1916697. View

Dijk F, Veenstra V, Soer E, Dings M, Zhao L, Halfwerk J . Unsupervised class discovery in pancreatic ductal adenocarcinoma reveals cell-intrinsic mesenchymal features and high concordance between existing classification systems. Sci Rep. 2020; 10(1):337. PMC: 6962149. DOI: 10.1038/s41598-019-56826-9. View

Neuzillet C, Tijeras-Raballand A, Ragulan C, Cros J, Patil Y, Martinet M . Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma. J Pathol. 2018; 248(1):51-65. PMC: 6492001. DOI: 10.1002/path.5224. View

Krug K, Mertins P, Zhang B, Hornbeck P, Raju R, Ahmad R . A Curated Resource for Phosphosite-specific Signature Analysis. Mol Cell Proteomics. 2018; 18(3):576-593. PMC: 6398202. DOI: 10.1074/mcp.TIR118.000943. View

Naro C, Bielli P, Sette C . Oncogenic dysregulation of pre-mRNA processing by protein kinases: challenges and therapeutic opportunities. FEBS J. 2021; 288(21):6250-6272. PMC: 8596628. DOI: 10.1111/febs.16057. View

10.

Masjedi A, Hajizadeh F, Beigi Dargani F, Beyzai B, Aksoun M, Hojjat-Farsangi M . Oncostatin M: A mysterious cytokine in cancers. Int Immunopharmacol. 2020; 90:107158. DOI: 10.1016/j.intimp.2020.107158. View

11.

Annunziata M, Parisi M, Esposito G, Fabbrocini G, Ammendola R, Cattaneo F . Phosphorylation Sites in Protein Kinases and Phosphatases Regulated by Formyl Peptide Receptor 2 Signaling. Int J Mol Sci. 2020; 21(11). PMC: 7312799. DOI: 10.3390/ijms21113818. View

12.

Schneider M, Hsiao H, Will C, Giet R, Urlaub H, Luhrmann R . Human PRP4 kinase is required for stable tri-snRNP association during spliceosomal B complex formation. Nat Struct Mol Biol. 2010; 17(2):216-21. DOI: 10.1038/nsmb.1718. View

13.

Hua H, Kong Q, Yin J, Zhang J, Jiang Y . Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy. J Hematol Oncol. 2020; 13(1):64. PMC: 7268628. DOI: 10.1186/s13045-020-00904-3. View

14.

Casado P, Rio-Machin A, Miettinen J, Bewicke-Copley F, Rouault-Pierre K, Krizsan S . Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes. Signal Transduct Target Ther. 2023; 8(1):80. PMC: 9968719. DOI: 10.1038/s41392-022-01288-1. View

15.

Zhang W, Sakashita S, Taylor P, Tsao M, Moran M . Comprehensive proteome analysis of fresh frozen and optimal cutting temperature (OCT) embedded primary non-small cell lung carcinoma by LC-MS/MS. Methods. 2015; 81:50-5. DOI: 10.1016/j.ymeth.2015.02.008. View

16.

Li Z, Liu J, Zhang J . 14-3-3sigma, the double-edged sword of human cancers. Am J Transl Res. 2009; 1(4):326-40. PMC: 2780041. View

17.

Zhu C, Guan X, Zhang X, Luan X, Song Z, Cheng X . Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Mol Cancer. 2022; 21(1):159. PMC: 9351107. DOI: 10.1186/s12943-022-01629-2. View

18.

Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H . Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007; 131(6):1190-203. DOI: 10.1016/j.cell.2007.11.025. View

19.

Connor A, Gallinger S . Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data. Nat Rev Cancer. 2021; 22(3):131-142. DOI: 10.1038/s41568-021-00418-1. View

20.

Shen H, Lundy J, Strickland A, Harris M, Swan M, Desmond C . G12D Mutation Subtype in Pancreatic Ductal Adenocarcinoma: Does It Influence Prognosis or Stage of Disease at Presentation?. Cells. 2022; 11(19). PMC: 9562007. DOI: 10.3390/cells11193175. View